Johnson and Johnson (JNJ) Reports Positive Phase 1b Cancer Data

Johnson & Johnson (NYSE:JNJ) is one of the 10 best stocks to invest in during a recession.

On February 26, 2026, Johnson & Johnson (NYSE:JNJ) provided an update, reporting promising Phase 1b data for pasritamig, a pioneering bispecific T-cell engager, combined with docetaxel for metastatic castration-resistant prostate cancer. The study was unveiled at the 2026 ASCO GU Symposium. The results showed no unexpected safety concerns, thereby mirroring docetaxel’s profile alone. Critically, the combination achieved durable reductions in prostate-specific antigen (PSA). According to Charles Drake, Vice President, Prostate Cancer and Cross Cancer Immuno-Oncology, Johnson & Johnson (NYSE:JNJ), this success has strengthened the company's foundation for Phase 3 development.

The ability to combine pasritamig with docetaxel, where prior approaches in the field have fallen short, gives us a strong foundation for Phase 3 development.

In another development, on February 24, 2026, Johnson & Johnson (NYSE:JNJ) announced that it had submitted a supplemental Biologics License Application to the U.S. FDA for IMAAVY® (nipocalimab-aahu). If approved, it would be the first treatment for warm autoimmune hemolytic anemia (wAIHA). The company’s Phase 2/3 ENERGY trial data indicated a rapid, durable hemoglobin response and significant improvement in fatigue for patients treated with the therapy.

Johnson & Johnson (NYSE:JNJ), founded in 1886, is a global multinational pharmaceutical, biotechnology, and medical technologies company, operating through two segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). Its headquarters is in New Jersey.

While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.